
WHAT IS CLAIMED IS:

1. An amorphous form of Compound (I) of the formula



(I).

2. The amorphous form of claim 1 characterized by PXRD as depicted in FIG. 1.

3. The amorphous form of claim 1 characterized by modulated DSC as depicted in FIG. 2.

4. The amorphous form of claim 1 characterized by PXRD as depicted in FIG. 3.

5. The amorphous form of claim 1 characterized by modulated DSC as depicted in FIG. 4.

6. The amorphous form of claim 1 characterized by solid-state NMR as depicted in FIG. 5.

7. A method for producing an amorphous solid dispersion of Compound (I), the method comprising:


(a) preparing a liquid solution comprising Compound (I), at least one polymer and a solvent; and

(b) spray drying the liquid solution, thereby producing the amorphous solid dispersion.

8. The method of claim 7, wherein the liquid solution comprises at least one solvent selected from the group consisting of: acetone, tetrahydrofuran, alcohol, ethyl acetate, methyl ethyl ketone, dichloromethane, and water.

9. The method of claim 7, wherein the polymer is selected from the group consisting of: PVP, PVP-vinyl acetate copolymer, HPMCAS, and HPMC.

10. An amorphous solid dispersion comprising Compound (I) of the formula



(I)

and a polymer wherein the polymer is selected from the group consisting of PVP, HPMCAS and HPMC,

wherein the ratio of Compound (I) to polymer is in the range of from 99% to 75% (w/w) Compound (I) and from 1% to 25% (w/w) polymer, or

wherein the ratio of Compound (I) to polymer is in the range of from 74% to 50% (w/w) Compound (I) and from 26% to 50% (w/w) polymer.

11. The amorphous solid dispersion of claim 10 wherein the polymer is HPMCAS.

12. The amorphous solid dispersion of claim 10 wherein the ratio of Compound (I) to polymer is in the range of from 99% to 75% (w/w) Compound (I) and from 1% to 25% (w/w) polymer.

13. The amorphous solid dispersion of claim 10 wherein the ratio of Compound (I) to polymer is in the range of from 74% to 50% (w/w) Compound (I) and from 26% to 50% (w/w) polymer.

14. The amorphous solid dispersion of claim 11, wherein the ratio of Compound (I) to polymer is 75% (w/w) Compound (I) and 25% (w/w) HPMCAS.

15. The amorphous solid dispersion of claim 11, wherein the ratio of Compound (I) to polymer is 50% (w/w) Compound (I) and 50% (w/w) HPMCAS.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the amorphous solid dispersion of claim 10.

17. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is in the form of a tablet.

18. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is in the form of a capsule.

19. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is in the form of a suspension.

20. The pharmaceutical composition of claim 17 or 18, wherein the tablet and capsule are storage stable for at least about 3 months.